Literature DB >> 30959137

Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients.

Beáta Soltész1, János Lukács2, Edina Szilágyi3, Éva Márton3, Melinda Szilágyi Bónizs3, András Penyige3, Róbert Póka2, Bálint Nagy3.   

Abstract

CD24 is a small molecular weight cell-surface protein and an independent marker for poor prognosis in the different type of cancers. We aimed to determine the expression of CD24 in plasma, exosomes and ovarian tissue samples of serous ovarian cancer patients. We collected tissue and blood samples from 21 cases of serous ovarian cancer and eight healthy controls. We used silica adsorption method for isolation of RNA. The cDNA was synthesized using quantitative real-time PCR. We used beta-globin as a housekeeping gene for the normalization of the data. Protein-protein and miRNA networking were analyzed. There was a significant difference in the expression of CD24 in ovarian tissue between controls and patients (0.16 ± 0.32 vs. 44.97 ± 68.06; p < 0.01), while CD24 did not show expression in each plasma and exosome samples. There was a correlation in the expression of CD24 and FIGO grading between controls and patients. CD24 expression was detected in exosomes in 38.1% of patients, mainly with FIGO III, and in their plasma in 9.5% of cases. Our network analysis shows LYN, SELP, FGR, and NPM1 proteins are interacting with CD24. Our study demonstrates higher expression of CD24 in ovarian cancer patients' tissue samples, and there is an association with FIGO classification. However, CD24 showed expression only in some cell-free plasma and exosome samples.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD24; Cell-free nucleic acids; Exosomes; Ovarian cancer; Plasma

Mesh:

Substances:

Year:  2019        PMID: 30959137     DOI: 10.1016/j.jbiotec.2019.03.018

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  7 in total

1.  Integrated single-cell analyses decode the developmental landscape of the human fetal spine.

Authors:  Haiyan Yu; Donge Tang; Hongwei Wu; Chunhong Li; Yongping Lu; Fang He; Xiaogang Zhang; Yane Yang; Wei Shi; Wenlong Hu; Zhipeng Zeng; Weier Dai; Minglin Ou; Yong Dai
Journal:  iScience       Date:  2022-06-27

Review 2.  Potentiality of Exosomal Proteins as Novel Cancer Biomarkers for Liquid Biopsy.

Authors:  Chunmiao Hu; Wei Jiang; Mingjin Lv; Shuhao Fan; Yujia Lu; Qingjun Wu; Jiang Pi
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 3.  The Role of Exosomes in the Female Reproductive System and Breast Cancers.

Authors:  Yuqi Bai; Jie Guo; Zhongshan Liu; Yunfeng Li; Shunzi Jin; Tiejun Wang
Journal:  Onco Targets Ther       Date:  2020-12-08       Impact factor: 4.147

Review 4.  Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers.

Authors:  Miaomiao Ye; Jing Wang; Shuya Pan; Lihong Zheng; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther Oncolytics       Date:  2021-12-09       Impact factor: 7.200

5.  CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance.

Authors:  Li-Yan Qiao; Han-Bing Li; Yue Zhang; Di Shen; Peng Liu; Yi-Qun Che
Journal:  Pharmgenomics Pers Med       Date:  2021-05-25

Review 6.  Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.

Authors:  Wookyeom Yang; Dasol Kim; Dae Kyoung Kim; Kyung Un Choi; Dong Soo Suh; Jae Ho Kim
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 7.  The Role and Clinical Interest of Extracellular Vesicles in Pregnancy and Ovarian Cancer.

Authors:  Nazanin Yeganeh Kazemi; Benoìt Gendrot; Ekaterine Berishvili; Svetomir N Markovic; Marie Cohen
Journal:  Biomedicines       Date:  2021-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.